Ezkerralde-Enkarterri-Gurutzetako Erakunde Sanitario Integratua
Osakidetzako erakundea
University of Glasgow
Glasgow, Reino UnidoUniversity of Glasgow-ko ikertzaileekin lankidetzan egindako argitalpenak (18)
2024
2022
2021
-
Mapping the human genetic architecture of COVID-19
Nature, Vol. 600, Núm. 7889, pp. 472-477
2020
-
Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data
The Lancet, Vol. 396, Núm. 10262, pp. 1574-1584
-
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial
The Lancet, Vol. 396, Núm. 10264, pp. 1745-1757
2017
-
Global, regional, and national age-sex specifc mortality for 264 causes of death, 1980-2016: A systematic analysis for the Global Burden of Disease Study 2016
The Lancet, Vol. 390, Núm. 10100, pp. 1151-1210
-
Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: A systematic analysis for the Global Burden of Disease Study 2016
The Lancet, Vol. 390, Núm. 10100, pp. 1084-1150
-
Healthcare access and quality index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: A novel analysis from the global burden of disease study 2015
The Lancet, Vol. 390, Núm. 10091, pp. 231-266
-
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer
Nature Genetics, Vol. 49, Núm. 12, pp. 1767-1778
-
Incidence of severe critical events in paediatric anaesthesia (APRICOT): a prospective multicentre observational study in 261 hospitals in Europe
The Lancet Respiratory Medicine, Vol. 5, Núm. 5, pp. 412-425
2015
-
Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1
American Journal of Medical Genetics, Part A, Vol. 167, Núm. 2, pp. 296-312
-
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
American Heart Journal, Vol. 169, Núm. 5, pp. 631-638.e7
-
Serumuric acidandthe riskof cardiovascular and renal disease
Journal of Hypertension, Vol. 33, Núm. 9, pp. 1729-1741
2014
-
Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): A large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia
BMJ Open, Vol. 4, Núm. 7
-
Up-titration of allopurinol in patients with gout
Seminars in Arthritis and Rheumatism, Vol. 44, Núm. 1, pp. 25-30
2004
-
Prenatal diagnostic procedures used in pregnancies with congenital malformations in 14 regions of Europe
Prenatal Diagnosis, Vol. 24, Núm. 11, pp. 908-912